



Financial Tear Sheet

Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

AVEO Oncology
Investor Relations
Phone: 617-588-1960
E-mail:
ir@aveooncology.com

Stock Performance

AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$2.90
Change (%)	▼ 0.01 (0.34%)
Volume	642,128
52 Week Low	\$0.50
Market Cap	\$345,785,473
Rolling EPS	-0.61
PE Ratio	N/A

Shares Outstanding 118,867,471

Data as of 03/20/18 1:42 p.m. ET



Recent Headlines

03/13/18
AVEO Reports Full Year 2017 Financial Results and Provides Business Update

03/06/18
AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference

02/12/18
AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma

Events

There are currently no events scheduled.

SEC Filings

FILING DATE FORM

03/13/18	8-K
03/13/18	10-K
02/16/18	424B5
02/16/18	8-K

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed